- Details
- Philip Koo discusses the newly updated PSMA PET/CT: Joint EANM, SNMMI procedure guideline, version 2.0, with its first and senior authors, Wolfgang Fendler and Ken Herrmann from Germany. The updated guideline, considered a landmark paper, integrates new ligands and types of imaging, consolidating information on PSMA imaging for different ligands and formalizing them as a class of ligands. It featu...
|
- Details
- Phillip Koo welcomes Ken Herrmann to discuss Herrmann’s team's latest article, "Tackling the Last Mile: A Major Component to Successfully Established Radioligand Therapy," arguing the importance of 'the last mile' of treatment delivery in nuclear medicine. Drawing parallels with the logistics industry, Herrmann emphasizes the need for flawless delivery of therapy to patients, with patient awarenes...
|
- Details
- David Crawford joins Phillip Koo in a discussion on the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) articles, which aimed to improve the appropriate utilization of imaging in prostate cancer patients. The RADAR articles looked at three areas: biochemical failure, newly diagnosed disease, and castrate-resistant non-metastatic disease. They suggested appropriate triggers fo...
|
- Details
- Philip Koo interviews Michael Kipper about the peer-to-peer PYLARIFY reader assistance program. Aimed at educating healthcare providers in accurately reading and interpreting PYLARIFY scans, the program seeks to enhance patient care and harmonize reporting across institutions. Dr. Kipper emphasizes that this initiative is not meant for over-reading studies but to extend understanding of PYLARIFY r...
|
- Details
- In a recent led by Phillip Koo, Andrei Gafita and Wolfgang Fendler provide valuable insights on their innovative research, demonstrating the potential of PSMA PET imaging as a response to therapy tool in prostate cancer. Their study highlights the inconsistencies between PSMA PET responders and PSA levels, with about 50% of patients exhibiting this discrepancy. They found that PSMA PET imaging may...
|
- Details
- Phillip Koo speaks with Masoom Haider about the potential of radiomics and machine learning in prostate cancer diagnosis and treatment. Dr. Haider explains that radiomics quantifies information in medical images, such as MRIs, to extract valuable data that can be analyzed using machine learning techniques. This could lead to better risk profiles for patients and more precise treatment plans. Howev...
|
- Details
- Sigrid Carlsson joins Phillip Koo in a discussion on Smart Screening in Prostate Cancer, a session being highlighted at the upcoming 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer taking place virtually September 22-24. The pair discuss challenges with screening today that require clinicians to be smarter about screening including the risk of overdiagnosis, incorporating...
|
- Details
- Wolfgang Fendler and Andrei Gafita join Phillip Koo in a discussion on the Journal of Nuclear Medicine publication "Measuring response in metastatic castration‑resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria". This study received partial funding from the Prostate Cancer Foundation (PCF). In order to move PSMA PET forward and shif...
|
- Details
- Ronaldo Baroni joins Phillip Koo at the 13th Uro-Oncology Congress in São Paulo, Brazil in a discussion highlighting Dr Baroni's lecture he gave on future perspectives in prostate imaging. Prostate MRI is already established as the standard modality for prostate detection prior to biopsy. Future perspectives include more rational and widespread use of prostate MRI including a more widely available...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss an article published in JAMA Network Open titled "Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer." This study aimed to evaluate the prognostic significance of a nomogram that models an individual's risk of nonlocaliz...
|
